Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …

For a blood-borne cancer therapeutic agent to be effective, it must cross the blood vessel
wall to reach cancer cells in adequate quantities, and it must overcome the resistance …

The oncofetal antigen Claudin 6 (CLDN6) is highly and specifically expressed in many solid
tumors, and could be a promising treatment target. We report dose escalation results from …

Sonodynamic therapy (SDT) exhibits high tissue penetration and negligible radiation
damage to normal tissues, and thus emerges as a promising cancer therapeutic modality for …

A major rate-limiting step in develo** more effective immunotherapies for GBM is our
inadequate understanding of the cellular complexity and the molecular heterogeneity of …

Glioblastoma multiforme (GBM) remains incurable despite aggressive implementation of
multimodal treatments after surgical debulking. Almost all patients with GBM relapse within a …

Background Gliomas are the most common malignant primary brain tumours with a highly
immunosuppressive tumour microenvironment (TME) and poor prognosis. Circular RNAs …

Glioblastoma (GBM) treatment has remained almost unchanged for more than 20 years. The
current standard of care involves surgical resection (if possible) followed by concomitant …

Immunotherapies have revolutionized intervention strategies for many primary cancers, but
have not improved the outcomes of glioblastoma multiforme (GBM), which remains one of …

Neutrophils are abundant immune cells in the circulation and frequently infiltrate tumors in
substantial numbers. However, their precise functions in different cancer types remain …